Differentiation of pancreatic endocrine cells
Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
1. A population of in vitro differentiated cells comprising NKX6.1-positive, ISL1-positive cells and NKX6.1-negative, ISL1-positive cells; wherein less than 6% of the cells in the population are NKX6.1-negative, ISL1-negative cells; wherein at least 70%, at least 73%, at least 75%, or at least 80% of the cells in the population are ISL1-positive cells; and wherein the population of cells are in one or more cell clusters.
2. The population of claim 1 , wherein less than 4% of the cells in the population are NKX6.1-negative, ISL1-negative cells.
3. The population of claim 1 , 3 to less than 6% or 3-5% of the cells in the population are NKX 6 .1-negative, ISL1-negative cells.
4. The population of claim 1 , wherein 70-90%, 70-85%, 70-80%, 70-75%, 75-90%, 75-85%, 75-80%, 80-90%, 80-85%, or 85-90% of the cells in the population are ISL1-positive cells.
5. The population of claim 1 , wherein at least 4% or at least 5% of the cells in the population are NKX6.1-negative, ISL1-negative cells.
6. The population of claim 1 , wherein at least 40% of the cells in the population are NKX6.1-negative, ISL1-positive cells.
7. The population of claim 1 , wherein at least 45%, at least 50%, about 40-50%, about 45-55%, or about 50-55% of the cells in the population are NKX6.1-negative, ISL1-positive cells.
8. The population of claim 1 , wherein at least 74%, at least 75%, at least 80%, at least 85%, at least 90%, about 85-95%, or about 90-95% of the cells in the population are ISL1-positive cells.
9. The population of claim 1 , wherein the population of cells is derived from stem cells in vitro.
10. The population of claim 1 , further comprising a medium.
11. The population of claim 10 , wherein the medium comprises a sugar.
12. The population of claim 10 , wherein the medium comprises the sugar at a concentration of between about 0.05% and about 1.5%.
13. The population of claim 10 , wherein the medium is a CMRL medium; or wherein the medium is a cryopreservation media.
14. The population of claim 1 , wherein the cell cluster is between about 125 and about 225 microns in diameter, between about 130 and about 160 microns in diameter, between about 170 and about 225 microns in diameter, between about 140 and about 200 microns in diameter, between about 140 and about 170 microns in diameter, between about 160 and about 220 microns in diameter, between about 170 and about 215 microns in diameter, or between about 170 and about 200 microns in diameter.
15. The population of claim 1 , wherein the population comprises cells having a genetic disruption in the beta-2-microglobulin gene.
16. The population of claim 1 , wherein the population is in an implantable encapsulation device.
17. The population of claim 1 , wherein a cluster of the one or more clusters comprises between 500-2500 cells.
18. The population of claim 1 , wherein the population comprises NKX6.1-positive, ISL1-positive cells that display a glucose stimulated insulin secretion (GSIS) response similar or superior to that of an endogenous mature β cell if tested in vitro.
19. The population of claim 1 , wherein at least about 35% of the cells in the population are C-peptide-positive, VMAT1-negative cells.
20. The population of claim 18 , wherein the population comprises NKX6.1-positive, ISL1-positive cells that exhibit a stimulation index of 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 or greater.
21. The population of claim 20 , wherein 80-95% of the cells in the population are ISL-positive cells.